Searchable abstracts of presentations at key conferences in endocrinology

ea0098t12 | Trials In Progress | NANETS2023

Neuroendocrine tumors AI-based clinical trial search tool eases clinical trial discovery for patients and health care professionals

Mailman Josh , Ralic Danielle , del Rivero MD Jaydira , Gericke MD Germo , Halfdanarson MD Thorvardur R. , Herrmann MD Ken , Hollander Ronald , Albert Fisher Jr. MD George

Background: Finding relevant neuroendocrine tumor (NET) trials remains a challenge for patients and healthcare professionals (HCPs). Clinicaltrials.gov’s taxonomy associates many conditions with NETs, complicating the discovery process. As of 6/30/23 clinicaltrials.gov listed 700 recruiting, phase 1-3 interventional trials using the terms Neuroendocrine Tumors, Pheochromocytoma, and Paraganglioma. Many of these trials are not relevant for patients with NETs. Even with sev...

ea0013s68 | A successful research career | SFEBES2007

MD VS PhD

Munir Alia

We are all aware of the current anxieties over the future of Academic Medicine and Modernising Medical Careers. 10 years ago the BMA cohort of 1995 Medical graduates: Medical Academic Career Intentions was performed. 545 doctors graduating in 1995 were followed up for 10 years. The key findings included: those doctors working in research were doing so to improve future career prospects or as a means to secure a National Training Number (NTN). However being in the transition pe...

ea0063p294 | Pituitary and Neuroendocrinology 1 | ECE2019

Menstrual dysfunction (MD) with ACTH dependent Cushing syndrome

Irgasheva Oydin , Yusupovna Khalimova Zamira

MD are the most frequent complaint of women with Cushing Syndrome at the time of diagnosis.Objective: To study the frequency of occurrence of MD in patients with Syndrome Cushing and to characterize their clinical and hormonal parallels. We investigated 34 women (average age of 27 years, variation in age from 18 to 30 years) with a newly identified ACTHA. The patients were divided into 4 groups: (1) the normal cycle is 26–31 days; (2) oligomenorrhea...

ea0098b26 | Basic Science | NANETS2023

Cancer testis antigen and interleukin expression correlates with survival in small bowel neuroendocrine tumors

David Seo MD Y. , Witt MD, MAS Russell G. , Lazcano MD Rossana , MD Samuel Cass , Hudgens Courtney , Wani Khalida , Chelvanambi PhD Manoj , Johnson MS Sarah , Hernandez MD Sharia D. , Halperin MD Daniel M. , Lazar MD, PhD Alexander J. , Wargo MD, MMSc Jennifer A. , Estrella MD Jeannelyn S. , Maxwell MD, MBA Jessica E.

Background: Patients with small bowel neuroendocrine tumors (SBNETs) frequently present with metastatic disease, and unfortunately, the range and efficacy of available therapies is limited. Immunotherapeutic checkpoint inhibitors have demonstrated benefit in other malignancies and may also play a role in SBNETs, although relatively little is known about the immune infiltrate in these tumors. Toward a goal of developing novel immunomodulatory strategies, we sought to evaluate t...

ea0011s105 | Presenting your research – getting your work known | ECE2006

PhD/MD Thesis: a recipe for success

Abayasekara DRE

In all probability, a thesis is the longest single document that anyone is likely to write as a scientist. It requires much planning to ensure that the thesis gets written and submitted on time. To begin with, plan the overall outline of the thesis. With some variation, most theses begin with a comprehensive introduction/literature review. A chapter describing the materials and methods invariably follows. The subsequent chapters contain the material you have sweated over i.e. ...

ea0032p392 | Diabetes | ECE2013

Potentialities of skin impedance spectroscopy in vivo in non-invasive monitoring of glucose level

Ivan Turkovskiy , Boris Paramonov , Vitaly Kharin , Monica Gericke , Nicolay Belyaev

Considered are the physiological mechanisms of relationship of the magnitude of blood plasma and interstitial fluid osmolarity conditioned by glycaemia with transmembrane movement of water between intra- and extracellular water compartments of organism. Analysed are the potentialities of impedance spectroscopy in quantitative evaluation of increments of specific volumes of extra- and intracellular fluid of hypoderm tissues occurring due to fluctuations of intercellular fluid g...

ea0089c2 | Clinical – Chemo/SSA/Biologics | NANETS2022

Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Neoplasms

Hunter, MD Lindsay A , Whisenant, MD Jonathan , Weldon Gilcrease, MD G.

Background: High-grade neuroendocrine neoplasms (HG-NENs) are a heterogenous and biologically aggressive rare subset of NENs. Few therapeutic options are available to metastatic HG-NENs. To date, first line treatment is platinum- or temozolomide-based chemotherapy which provide modest benefits in overall survival (OS) and progression free survival (PFS). Given the promising activity of immunotherapy across several cancer types, our center initiated a phase II trial of pembroli...

ea0094op4.2 | Thyroid | SFEBES2023

Primary thyroid sarcoma: a case report

Melissa Cielo, MD Frances

Background: Undifferentiated pleomorphic sarcoma (UPS) of the thyroid is rare. It is often identified in its advanced stage, with distant metastasis, and has poor prognosis. This paper presents one of the less than 30 cases that have been documented ever since it was first identified in 1989. In the Philippines, there is no published report of a primary thyroid sarcoma.Case Presentation: The author describes a 73-year-ol...

ea0098c33 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

DOTATATE PET/CT imaging in prostate cancer: incidental observations and potential future implications

E Salem MD, PhD Ahmed , Soares MD Heloisa P. , Fine MD Gabriel C , Morton MD. Kathryn A

Background: Hormonally-refractory, lethal forms of PCa may express neuroendocrine features, including PCa with neuroendocrine differentiation (NEDPCa) and treatment emergent small cell neuroendocrine PCa (tSCNC). We hypothesize that some lethal metastatic PCa may show higher expression of SSTR than of PSMA and that a dual imaging approach with PET radiopharmaceuticals targeting these moieties will enable informed selection of patients for the future corresponding therapeutic r...

ea0098c39 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Repeat peptide receptor radionuclide therapy in neuroendocrine neoplasms: a NET center of excellence experience

Grewal, MD Udhayvir Singh , Paschke, MD Alexander , Dillon, MD Joseph , Chandrasekharan, MD Chandrikha

Background: Lu177 DOTATATE Peptide Receptor Radionucleotide Therapy (PRRT) was FDA approved in the United States in 2018, however, the data for the safety and efficacy of repeat PRRT are almost exclusively from European centers. We present an updated experience with repeat PRRT in a cohort of US patients.Methods: We used our single-center longitudinal IRB approved neuroendocrine tumor (NET) registry to identify patients who had been previously treated wi...